Association of Serum Eosinophilic Cationic Protein With Disease Severity in Infant Bronchiolitis

Selcen Bedir1, Yılmaz Seçilmiş2

  • 1Department of Pediatrics.

Insights

Serum eosinophilic cationic protein (ECP) did not diagnose bronchiolitis but showed higher levels in severe cases and with tobacco smoke exposure. ECP may reflect inflammatory phenotypes, not predict severity independently.

Area of Science:

  • Pediatric Respiratory Medicine
  • Clinical Immunology
  • Biomarker Research

Background:

  • Acute bronchiolitis is a common respiratory infection in infants.
  • Identifying reliable biomarkers for disease severity is crucial for clinical management.
  • Tobacco smoke exposure is a known risk factor for respiratory illnesses.

Purpose of the Study:

  • To evaluate serum eosinophilic cationic protein (ECP) levels in children with acute bronchiolitis versus healthy controls.
  • To investigate the association of serum ECP with clinical severity and tobacco smoke exposure.
  • To assess ECP's potential as a diagnostic or prognostic biomarker.

Main Methods:

  • Prospective cross-sectional study of 96 infants with bronchiolitis and 96 controls (1-24 months).
  • Serum ECP levels and routine labs measured; associations with severity indicators (ICU admission, ventilation) and smoke exposure analyzed.
  • Multivariable logistic regression used to identify predictors of severe bronchiolitis.

Main Results:

  • Serum ECP levels did not differ between bronchiolitis patients and controls.
  • Higher ECP levels were found in severe cases (ICU admission, ventilation) and with tobacco smoke exposure.
  • ECP correlated with leukocyte counts and glucose; tobacco smoke exposure was an independent predictor of severity.

Conclusions:

  • Serum ECP lacks independent prognostic utility for acute bronchiolitis.
  • Elevated ECP in severe, smoke-exposed cases suggests it reflects inflammatory phenotypes.
  • ECP is not a direct clinical risk stratification tool for bronchiolitis severity.
Abstract

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
2
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
2
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
5.0K
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
2
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K